GW&K Investment Management LLC bought a new position in Emergent Biosolutions Inc (NYSE:EBS) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 4,310 shares of the biopharmaceutical company’s stock, valued at approximately $200,000.
Several other large investors have also recently bought and sold shares of the stock. Northern Trust Corp raised its position in Emergent Biosolutions by 47.2% during the second quarter. Northern Trust Corp now owns 906,731 shares of the biopharmaceutical company’s stock valued at $30,747,000 after purchasing an additional 290,863 shares during the period. Dimensional Fund Advisors LP raised its position in Emergent Biosolutions by 7.4% during the second quarter. Dimensional Fund Advisors LP now owns 2,205,712 shares of the biopharmaceutical company’s stock valued at $74,795,000 after purchasing an additional 152,029 shares during the period. Peregrine Capital Management LLC raised its position in Emergent Biosolutions by 40.8% during the third quarter. Peregrine Capital Management LLC now owns 454,857 shares of the biopharmaceutical company’s stock valued at $18,399,000 after purchasing an additional 131,692 shares during the period. Renaissance Technologies LLC raised its position in Emergent Biosolutions by 16.7% during the second quarter. Renaissance Technologies LLC now owns 820,411 shares of the biopharmaceutical company’s stock valued at $27,820,000 after purchasing an additional 117,700 shares during the period. Finally, Acadian Asset Management LLC raised its position in Emergent Biosolutions by 6.2% during the fourth quarter. Acadian Asset Management LLC now owns 1,445,412 shares of the biopharmaceutical company’s stock valued at $67,165,000 after purchasing an additional 84,713 shares during the period. Institutional investors own 88.53% of the company’s stock.
Shares of Emergent Biosolutions Inc (EBS) opened at $50.82 on Wednesday. The company has a quick ratio of 6.46, a current ratio of 7.37 and a debt-to-equity ratio of 0.38. Emergent Biosolutions Inc has a fifty-two week low of $27.94 and a fifty-two week high of $51.25. The firm has a market capitalization of $2,490.52, a P/E ratio of 30.07, a PEG ratio of 1.03 and a beta of 1.25.
In other news, CEO Daniel Abdun-Nabi sold 31,508 shares of the stock in a transaction that occurred on Friday, November 3rd. The stock was sold at an average price of $42.77, for a total value of $1,347,597.16. Following the sale, the chief executive officer now directly owns 215,642 shares in the company, valued at $9,223,008.34. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Zsolt Harsanyi sold 7,000 shares of the stock in a transaction that occurred on Thursday, December 7th. The stock was sold at an average price of $42.47, for a total value of $297,290.00. Following the completion of the sale, the director now owns 37,077 shares in the company, valued at $1,574,660.19. The disclosure for this sale can be found here. Over the last quarter, insiders sold 206,329 shares of company stock worth $8,892,362. Company insiders own 16.50% of the company’s stock.
A number of equities research analysts have issued reports on the company. Chardan Capital upped their price objective on Emergent Biosolutions from $47.00 to $53.00 and gave the company a “buy” rating in a research report on Tuesday, January 16th. Zacks Investment Research downgraded Emergent Biosolutions from a “strong-buy” rating to a “hold” rating in a research report on Thursday, January 11th. Finally, Wells Fargo & Co restated an “outperform” rating and set a $43.00 price objective (up from $41.00) on shares of Emergent Biosolutions in a research report on Saturday, September 30th.
TRADEMARK VIOLATION WARNING: This article was originally reported by Community Financial News and is the property of of Community Financial News. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The correct version of this article can be accessed at https://www.com-unik.info/2018/01/24/gwk-investment-management-llc-acquires-new-position-in-emergent-biosolutions-inc-ebs.html.
Emergent Biosolutions Profile
Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).
Want to see what other hedge funds are holding EBS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Emergent Biosolutions Inc (NYSE:EBS).
Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.